NovaBay posts $1.5 million quarterly loss

NovaBay Pharmaceuticals reported a net loss of $1.5 million, or $0.09 per share, in the third quarter of 2018 compared with a net loss of $2.4 million, or $0.16 per share, in 2017’s third quarter.

Net sales were down from $4.1 million to $3.1 million for the quarter, which the company attributed to a lower selling price of Avenova, a press release said.

Sales and marketing expenses were $3.2 million for the quarter compared with $3.3 million in the same quarter of last year, while general and administrative expenses for the quarter were down from $2.3 million to $1.3 million.

NovaBay had cash and cash equivalents totaling $5.2 million as of Sept. 30.

NovaBay Pharmaceuticals reported a net loss of $1.5 million, or $0.09 per share, in the third quarter of 2018 compared with a net loss of $2.4 million, or $0.16 per share, in 2017’s third quarter.

Net sales were down from $4.1 million to $3.1 million for the quarter, which the company attributed to a lower selling price of Avenova, a press release said.

Sales and marketing expenses were $3.2 million for the quarter compared with $3.3 million in the same quarter of last year, while general and administrative expenses for the quarter were down from $2.3 million to $1.3 million.

NovaBay had cash and cash equivalents totaling $5.2 million as of Sept. 30.